the Prevalence of UGT1A1*93 and ABCC5 Polymorphisms in Cancer Patients Receiving Irinotecan-Based Chemotherapy at Al-Najaf Al-Ashraf

• Váldodahkkit: ahmed F. al_talkani (Dahkki), Sarmed H. Kathem (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: College of Pharmacy University of Baghdad, 2019-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Irinotecan (CPT-11) is a semisynthetic derivative of the antineoplastic agent camptothecin used in a wide range as an anti-cancer agent in many solid tumors because of its cytotoxic effect through the interaction with the topoisomerase I enzyme. The major limiting factors for irinotecan treatment ar...